Clene (CLNN) versus Its Rivals Critical Analysis

Clene (NASDAQ:CLNN) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Clene to related businesses based on the strength of its dividends, risk, earnings, profitability, analyst recommendations, valuation and institutional ownership.

Earnings & Valuation

This table compares Clene and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Clene	$200,000.00	-$26.17 million	-1.52
Clene Competitors	$3.52 billion	$3.15 billion	554.50

Clene’s peers have higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

23.3% of Clene shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Clene and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1	0	6	0	2.71
Clene Competitors	7792	13886	25778	1037	2.41

Clene currently has a consensus target price of $34.00, indicating a potential upside of 760.76%. As a group, “Pharmaceuticals” companies have a potential upside of 25.53%. Given Clene’s stronger consensus rating and higher possible upside, research analysts clearly believe Clene is more favorable than its peers.

Risk and Volatility

Clene has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Clene’s peers have a beta of -3.71, suggesting that their average share price is 471% less volatile than the S&P 500.

Profitability

This table compares Clene and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clene	-11,274.79%	N/A	-77.56%
Clene Competitors	-2,380.38%	-217.94%	-15.54%

Summary

Clene peers beat Clene on 7 of the 13 factors compared.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.